Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.

Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW.

Oncotarget. 2018 Jan 15;9(10):8810-8822. doi: 10.18632/oncotarget.24256. eCollection 2018 Feb 6.

2.

Novel multi‑kinase inhibitor, T03 inhibits Taxol‑resistant breast cancer.

Li Y, Liu C, Tang K, Chen Y, Tian K, Feng Z, Chen J.

Mol Med Rep. 2018 Feb;17(2):2373-2383. doi: 10.3892/mmr.2017.8179. Epub 2017 Nov 28.

3.

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.

Osada T, Morse MA, Hobeika A, Diniz MA, Gwin WR, Hartman Z, Wei J, Guo H, Yang XY, Liu CX, Kaneko K, Broadwater G, Lyerly HK.

Oncoimmunology. 2017 Apr 12;6(6):e1315495. doi: 10.1080/2162402X.2017.1315495. eCollection 2017.

4.

Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.

Timmermans-Sprang EPM, Gracanin A, Mol JA.

Front Vet Sci. 2017 Apr 13;4:53. doi: 10.3389/fvets.2017.00053. eCollection 2017. Review.

5.

HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells.

Bai J, Zhou G, Qiu Y, Hu Y, Liu J, Zhao J, Zhang S, Zhang J.

Cancer Sci. 2017 Jun;108(6):1177-1184. doi: 10.1111/cas.13238. Epub 2017 May 19.

6.

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E.

J Clin Oncol. 2016 Dec 20;34(36):4345-4353. Epub 2016 Oct 23.

7.

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.

8.

Simvastatin suppresses breast cancer cell proliferation induced by senescent cells.

Liu S, Uppal H, Demaria M, Desprez PY, Campisi J, Kapahi P.

Sci Rep. 2015 Dec 14;5:17895. doi: 10.1038/srep17895.

9.

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.

Agrawal A, Robertson JF, Cheung KL, Gutteridge E, Ellis IO, Nicholson RI, Gee JM.

Int J Cancer. 2016 Jan 1;138(1):146-59. doi: 10.1002/ijc.29682. Epub 2015 Jul 30.

10.

ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.

Madhavan S, Gusev Y, Singh S, Riggins RB.

J Exp Clin Cancer Res. 2015 May 15;34:45. doi: 10.1186/s13046-015-0150-9.

11.

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT.

Oncoimmunology. 2014 Dec 21;3(11):e956012. eCollection 2014 Nov.

12.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

BMC Cancer. 2015 Apr 8;15:239. doi: 10.1186/s12885-015-1210-4.

14.

Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

Ren XR, Wang J, Osada T, Mook RA Jr, Morse MA, Barak LS, Lyerly HK, Chen W.

Breast Cancer Res. 2015 Feb 15;17:20. doi: 10.1186/s13058-015-0528-9.

15.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Larsen SL, Laenkholm AV, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015.

16.

Altered radiation responses of breast cancer cells resistant to hormonal therapy.

Luzhna L, Lykkesfeldt AE, Kovalchuk O.

Oncotarget. 2015 Jan 30;6(3):1678-94.

17.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.

18.

Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.

Zhao M, Ramaswamy B.

World J Clin Oncol. 2014 Aug 10;5(3):248-62. doi: 10.5306/wjco.v5.i3.248. Review.

19.

C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.

Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, Shilo K, Ganju RK.

Breast Cancer Res. 2014 May 29;16(3):R54. doi: 10.1186/bcr3665.

20.

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.

Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, Yang G.

Breast Cancer Res. 2013 Nov 29;15(6):R114. doi: 10.1186/bcr3581.

Supplemental Content

Support Center